A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (COC-IDCB)
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Chemotherapy, Safety, Tolerability, Efficacy
Eligibility Criteria
Inclusion Criteria:
- Patients ≥ 18 years of age with histologically proven infiltrating ductal carcinoma of breast
- no severe major organ dysfunction
- Patients must have adequate hematopoietic function as evidenced by:
white blood cells (WBC) ≥ 3,000/μl absolute neutrophil count (ANC) ≥ 1,500/μl Platelet count ≥ 100,000/μl hemoglobin (HGB) ≥ 10 g/dl and not transfusion dependent
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 10% above upper limit of normal
- Individuals of child-bearing potential must have a negative serum or urine pregnancy test within 72 hours of Cycle 1 Day 1.
- World Health Organization (WHO) performance status of 0 or 1
- No prior or concurrent cancer-associated chemotherapy, no initiation of new hormonal therapy
- Hormone receptor (estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (Her2)) status not specified
- Menopausal status not specified
- Patients or their legal representatives must be willing and able to provide written informed consent
- A Clinical Stage ≥ I subtype A (IA) (T1a, N0, M0) of Beast Cancer but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer-PrimaryTumor, Regional Nodes and Metastasis (TNM) staging system) as determined by a preoperative evaluation that included a chest computed tomography (CT) scan and/or X-ray mammography.
Exclusion Criteria:
- Age < 18
- Severe major organ dysfunction
- WHO performance status of >1
- Prior cancer chemotherapy
- Stage IV
- Patients with symptomatic central nervous system (CNS) metastases from breast cancer
- Patients with a history of another invasive malignancy within the last 3 years
- History of loss of consciousness or transient ischemic attack within 12 months before study treatment initiation.
- Patients who have known active HIV, Hepatitis B, or Hepatitis C infections.
- Patients with any other condition which in the opinion of the investigator would preclude participation in the study.
Sites / Locations
- Ganzhou City People's HospitalRecruiting
- China-Japan Union Hospital, Jilin UniversityRecruiting
- Shanghai 10th People's Hospital, Tongji University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Mono-chemotherapy
Combined chemotherapy
Placebo treatment
A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy. Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate.
Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer. Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate.
No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.